Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ADMA Biologics (ADMA)

ADMA Biologics reports 2025 revenue of $510 million, up 20%; CFO Brad Tade retires

Mixed Impact 4 of 5 earnings Written later

ADMA Biologics reported full-year 2025 total revenue of $510.2 million, up 20% from 2024, and reiterated its 2026-2029 financial guidance. GAAP net income fell to $146.9 million from $197.7 million, which included an $84.3 million one-time tax benefit in 2024. CFO Brad Tade is retiring and Terry Kohler becomes CFO on February 26, 2026.

Key points

  • Full-year 2025 revenue was $510.2 million, up from $426.5 million in 2024; ASCENIV revenue rose 51% to $363 million.
  • GAAP net income was $146.9 million in 2025 versus $197.7 million in 2024, which included an $84.3 million non-recurring tax benefit; Adjusted Net Income rose 35% to $160.8 million.
  • Terry Kohler, previously Executive Financial Advisor, was promoted to CFO and Treasurer effective February 26, 2026, succeeding Brad Tade.
  • Tade will serve as a consultant through July 31, 2026, at a monthly gross amount of $41,666.67; the company expects FY 2026 revenue to exceed $635 million.

The filing

CompanyADMA Biologics (ADMA)
Form8-K, current report
Filed with the SECFeb 25, 2026, 4:11 PM ET
Accession number0001140361-26-006781

Items reported: 2.02 Results of Operations5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.